J. Travins

发表

MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.

A. Kernytsky, S. Choe, K. Marks, 2016, Cell reports.

AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations.

Hua Yang, Fang Wang, Zenon Konteatis, 2017, Cancer discovery.

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

S. Gross, Giovanni Cianchetta, Cheng Fang, 2018, ACS medicinal chemistry letters.

A small molecule inhibitor of mutant IDH2 rescues cardiomyopathy in a D-2-hydroxyglutaric aciduria type II mouse model

A. Kernytsky, Yaguang Si, S. Gross, 2016, Journal of Inherited Metabolic Disease.

AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo

A. Melnick, R. Levine, P. Ward, 2014 .

AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant Model

P. Opolon, Hua Yang, K. Yen, 2014 .

Design and Enantioselective Synthesis of a Peptidomimetic of the Turn in the Helix-Turn-Helix DNA-Binding Protein Motif.

F. Etzkorn, J. Travins, 1997, The Journal of organic chemistry.

Facile synthesis of d-amino acids from an l-serine-derived aziridine

F. Etzkorn, J. Travins, 1998 .

Rare Protein Turns: γ‐Turn, Helix—Turn—Helix, and cis‐Proline Mimics

S. Hart, F. Etzkorn, J. Travins, 2000 .

Aspartic protease inhibitors: expedient synthesis of 2-substituted statines.

D. Veber, D. Rich, M. Bursavich, 2001, Organic letters.

Stereoselective deuterium labeling of proR beta-protons in the NMR structure determination of a helix-turn-helix turn peptide mimic.

F. Etzkorn, J. Travins, 2000, The journal of peptide research : official journal of the American Peptide Society.

Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation

Fang Wang, Erica Hansen, Francesco G. Salituro, 2013, Science.

Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation

R. Verhaak, K. Ligon, Hai Yan, 2012, Nature.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer

K. Ross, S. Ramaswamy, Kwok-Kin Wong, 2014, Nature.

IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.

Wei Liu, Fang Wang, Hua Yang, 2014, Blood.

Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo.

S. Gross, Shunqi Yan, J. Saunders, 2012, ACS medicinal chemistry letters.

MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage.

W. Liu, K. Marks, S. Gross, 2021, Cancer cell.

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Francine E. Garrett-Bakelman, C. Mason, A. Melnick, 2017, Cancer discovery.

1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.

Anna Wilhelmsson, P. Nambi, R. Bernotas, 2010, Bioorganic & medicinal chemistry letters.

4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.

Anna Wilhelmsson, P. Nambi, M. Evans, 2010, Bioorganic & medicinal chemistry letters.

Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.

Anna Wilhelmsson, James Jetter, P. Nambi, 2010, Bioorganic & medicinal chemistry letters.

Triazolopyridazines as tyrosine kinase

Tianbao Lu, M. Cummings, A. Maroney, 2006 .

Design and synthesis of polyethylene glycol-modified biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.

B. Tomczuk, C. Molloy, R. Bone, 2012, Bioorganic & medicinal chemistry letters.

Biphenylsulfonyl-thiophene-carboxamidine inhibitors of the complement component C1s.

B. Tomczuk, R. DesJarlais, Hui-Sheng Huang, 2008, Bioorganic & medicinal chemistry letters.

A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.

B. Tomczuk, R. DesJarlais, Hui-Sheng Huang, 2006, Bioorganic & medicinal chemistry letters.

AG-221 Offers a Survival Advantage In a Primary Human IDH2 Mutant AML Xenograft Model

S. Choe, Hua Yang, K. Yen, 2013 .

Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia.

Francine E. Garrett-Bakelman, C. Mason, A. Melnick, 2017, Cancer discovery.